SCHEMBL4774003

SCHEMBL4774003

ClCc1ccnc(-c2ccc3ccccc3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
KLF5 Q13887 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP11B1 P15538 3/20 0.42
CYP11B2 P19099 3/20 0.42
CDC25A P30304 1/20 0.42
CDC25B P30305 1/20 0.42
CDC25C P30307 1/20 0.42
DUSP3 P51452 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768794 0.84 CYP1A2 (0.44) CYP1A2SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL4775515 0.81 ASIC3 (0.50) ALDH1A1KDM4ECYP11B1CYP11B2NPC1
SCHEMBL4116786 0.81 ASIC3 (0.53) SMN1; SMN2ALDH1A1KDM4ECYP11B1CYP11B2
SCHEMBL25954683 0.79 MAPKAPK2 (0.53) CYP1A2SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL29558394 0.76 CCR1 (0.42) CYP1A2KDM4ELMNATSHRLOXL2
SCHEMBL1681797 0.76 CCR1 (0.42) CYP1A2KDM4ELMNATSHRLOXL2
SCHEMBL4128508 0.76 MAP4K4 (0.46) CYP1A2SMN1; SMN2KDM4EMAPTLMNA
Hydrochloric Acid SCHEMBL4427907 0.75 KMO (0.53) SMN1; SMN2ALDH1A1KDM4EMAPTTP53
SCHEMBL4120500 0.75 CYP11B1 (0.46) CYP1A2ALDH1A1KDM4ECYP11B1CYP11B2
SCHEMBL18334883 0.75 NPC1 (0.50) CYP1A2SMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100491352-C Asymmetrical cyclic diamine compound KOWA CO (JP) 2009-05-27 CN disclosed
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
CN-1520402-A Unsymmetrical cyclic diamine compound ������������ʽ���� 2004-08-11 CN disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 CYP1A2 1383/4885SMN1; SMN2 2573/4885ALDH1A1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.